Free Trial
→ Wall Street legend reveals his top AI stock before Oct. 20 (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:IMUX

Immunic Q2 2026 Earnings Results & Report

Immunic logo
$6.88 -0.02 (-0.22%)
As of 09:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunic beat analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.80 versus the -$1.16 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Immunic EPS Results

Actual EPS
-$0.80
Consensus EPS
-$1.16
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Immunic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Immunic's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunic's Q2 2026 Press ReleasePress Release
(8-K)
Immunic's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Immunic Q2 2026 Earnings FAQ

Immunic (NASDAQ:IMUX) reported earnings of -$0.80 per share for Q2 2026, beating the consensus estimate of -$1.16. The report was announced on Tuesday, August 11, 2026.

Immunic's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immunic on the company's earnings history page.

Immunic Earnings Headlines

Stifel Nicolaus Remains a Buy on Immunic (IMUX)
October 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMUX/pressreleases/5354282/stifel-nicolaus-remains-a-buy-on-immunic-imux/
Immunic (NASDAQ:IMUX) Stock Bumped Down to "Sell" by Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104280
My next big call (under $1)
The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.tc pixel
October 14 at 1:00 AM  |  Crypto 101 Media (Ad)
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 the 10th Joint ACTRIMS-ECTRIMS Meeting
October 8, 2026  |  marketscreener.comM
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
October 7, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099751?snapi
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
October 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/immunic-to-present-new-clinical-biomarker-and-preclinical-data-on-vidofludimus-calcium-at-mstoronto2026--the-10th-joint-actrims-ectrims-meeting-302901094.html
See More Immunic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email.

About Immunic

Immunic (NASDAQ:IMUX) is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease. Immunic is also advancing earlier-stage programs such as IMU-856, which targets Sirtuin 6 and is being evaluated for intestinal disorders, and IMU-381, an investigational molecule intended for immune-mediated diseases.

Immunic was established in 2016 and became a publicly traded company in 2019 through a merger with Vital Therapies, subsequently adopting the Immunic name. The company maintains operations in the United States and Germany, including corporate activities in Waltham, Massachusetts, and research and development operations in Germany. Its programs are investigational and remain subject to clinical testing and regulatory review.

View Immunic Profile
Earnings Tools